Caplin Point Laboratories unit Caplin Steriles receives USFDA approval for Calcium Gluconate Injection, expanding its U.S. injectable portfolio.
Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories, has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Calcium Gluconate Injection USP. This approval encompasses the 100 mg/mL strength in 10 mL, 50 mL, and 100 mL vials, positioning it as a generic therapeutic equivalent to the Reference Listed Drug (RLD) from Fresenius Kabi USA, LLC.
Calcium Gluconate Injection is a critical medication used in both pediatric and adult patients primarily for the treatment of acute symptomatic hypocalcemia, a condition characterized by low calcium levels in the blood. Beyond hypocalcemia, it also finds application in managing hyperkalemia (high blood potassium) and magnesium intoxication, and can be used to decrease the permeability of abnormally permeable capillaries and as an aid in treating allergic reactions. The injection works by increasing calcium levels in the body, a mineral vital for strong bones and heart health.
This USFDA approval is a significant milestone for Caplin Steriles, marking its 54th ANDA clearance in the U.S. market. The market for Calcium Gluconate Injection in the specified strengths had U.S. sales of approximately $71 million for the 12-month period ending March 2026, according to IQVIA™ (IMS Health) data. This provides a substantial commercial opportunity for Caplin Steriles to enter an established and essential therapeutic segment.
The approval carries broader implications for Caplin Steriles and the Indian pharmaceutical industry. For Caplin Steriles, it strengthens its growing U.S. injectable portfolio and underscores its capability to compete in highly regulated markets beyond its traditional focus on Latin American and African emerging markets. This regulatory success validates the company's investment in compliant infrastructure and disciplined quality systems at its Chennai-based facility, demonstrating its ability to meet the stringent aseptic manufacturing standards and regulatory scrutiny of the USFDA.
Economically, this approval is expected to diversify Caplin Point Laboratories' revenue streams and potentially reduce its reliance on emerging markets. It also reinforces the increasing presence and competitiveness of Indian Contract Development and Manufacturing Organizations (CDMOs) in the U.S. generics market, particularly in the sterile injectables segment where supply reliability and regulatory compliance are paramount. The company has a robust pipeline, with plans to file over 55 additional injectable and ophthalmic products in the next four years, further solidifying its global expansion strategy.
